Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms

A. Cartwright, SJ. Webster, A. de Jong, RJ. Dirven, LDS. Bloomer, AM. Al-Buhairan, U. Budde, C. Halldén, D. Habart, J. Goudemand, IR. Peake, JCJ. Eikenboom, AC. Goodeve, DJ. Hampshire

. 2020 ; 4 (13) : 2979-2990. [pub] 20200714

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020355

Grant support
P01 HL081588 NHLBI NIH HHS - United States
P01 HL144457 NHLBI NIH HHS - United States
R01 HL139847 NHLBI NIH HHS - United States
MR/K015753/1 Medical Research Council - United Kingdom

Copy number variation (CNV) is known to cause all von Willebrand disease (VWD) types, although the associated pathogenic mechanisms involved have not been extensively studied. Notably, in-frame CNV provides a unique opportunity to investigate how specific von Willebrand factor (VWF) domains influence the processing and packaging of the protein. Using multiplex ligation-dependent probe amplification, this study determined the extent to which CNV contributed to VWD in the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease cohort, highlighting in-frame deletions of exons 3, 4-5, 32-34, and 33-34. Heterozygous in vitro recombinant VWF expression demonstrated that, although deletion of exons 3, 32-34, and 33-34 all resulted in significant reductions in total VWF (P < .0001, P < .001, and P < .01, respectively), only deletion of exons 3 and 32-34 had a significant impact on VWF secretion (P < .0001). High-resolution microscopy of heterozygous and homozygous deletions confirmed these observations, indicating that deletion of exons 3 and 32-34 severely impaired pseudo-Weibel-Palade body (WPB) formation, whereas deletion of exons 33-34 did not, with this variant still exhibiting pseudo-WPB formation similar to wild-type VWF. In-frame deletions in VWD, therefore, contribute to pathogenesis via moderate or severe defects in VWF biosynthesis and secretion.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020355
003      
CZ-PrNML
005      
20210830102049.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2018027813 $2 doi
035    __
$a (PubMed)32609846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cartwright, Ashley $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
245    10
$a Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms / $c A. Cartwright, SJ. Webster, A. de Jong, RJ. Dirven, LDS. Bloomer, AM. Al-Buhairan, U. Budde, C. Halldén, D. Habart, J. Goudemand, IR. Peake, JCJ. Eikenboom, AC. Goodeve, DJ. Hampshire
520    9_
$a Copy number variation (CNV) is known to cause all von Willebrand disease (VWD) types, although the associated pathogenic mechanisms involved have not been extensively studied. Notably, in-frame CNV provides a unique opportunity to investigate how specific von Willebrand factor (VWF) domains influence the processing and packaging of the protein. Using multiplex ligation-dependent probe amplification, this study determined the extent to which CNV contributed to VWD in the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease cohort, highlighting in-frame deletions of exons 3, 4-5, 32-34, and 33-34. Heterozygous in vitro recombinant VWF expression demonstrated that, although deletion of exons 3, 32-34, and 33-34 all resulted in significant reductions in total VWF (P < .0001, P < .001, and P < .01, respectively), only deletion of exons 3 and 32-34 had a significant impact on VWF secretion (P < .0001). High-resolution microscopy of heterozygous and homozygous deletions confirmed these observations, indicating that deletion of exons 3 and 32-34 severely impaired pseudo-Weibel-Palade body (WPB) formation, whereas deletion of exons 33-34 did not, with this variant still exhibiting pseudo-WPB formation similar to wild-type VWF. In-frame deletions in VWD, therefore, contribute to pathogenesis via moderate or severe defects in VWF biosynthesis and secretion.
650    _2
$a variabilita počtu kopií segmentů DNA $7 D056915
650    _2
$a lidé $7 D006801
650    _2
$a Weibel-Paladeho granula $7 D020302
650    12
$a von Willebrandova nemoc, typ 1 $7 D056725
650    12
$a von Willebrandova nemoc $x diagnóza $x genetika $7 D014842
650    _2
$a von Willebrandův faktor $x genetika $7 D014841
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Webster, Simon J $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
700    1_
$a de Jong, Annika $u Einthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Dirven, Richard J $u Einthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Bloomer, Lisa D S $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
700    1_
$a Al-Buhairan, Ahlam M $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
700    1_
$a Budde, Ulrich $u Hämostaseology, Medilys Laborgesellschaft mbH, Hamburg, Germany
700    1_
$a Halldén, Christer $u Department of Environmental Science and Biomedicine, Kristianstad University, Kristianstad, Sweden
700    1_
$a Habart, David $u Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Goudemand, Jenny $u Centre de Référence Maladie de Willebrand, Hématologie, Hôpital Cardiologique, Lille, France; and
700    1_
$a Peake, Ian R $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
700    1_
$a Eikenboom, Jeroen C J $u Einthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Goodeve, Anne C $u Haemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
700    1_
$a Hampshire, Daniel J $u Department of Biomedical Sciences, University of Hull, Hull, United Kingdom
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 4, č. 13 (2020), s. 2979-2990
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32609846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102049 $b ABA008
999    __
$a ok $b bmc $g 1691015 $s 1140801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 4 $c 13 $d 2979-2990 $e 20200714 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
GRA    __
$a P01 HL081588 $p NHLBI NIH HHS $2 United States
GRA    __
$a P01 HL144457 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL139847 $p NHLBI NIH HHS $2 United States
GRA    __
$a MR/K015753/1 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options